Wednesday, June 17, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 14 of 1,261
  1. US 12414943

    Nimodipine parenteral administration

    Grace Therapeutics U.S., Inc. · Granted Sep 16, 2025 · Expires Sep 11, 2045

    granted
  2. US 12414983

    CD200AR ligands for cancer immunotherapy

    Regents of the University of Minnesota · Granted Sep 16, 2025 · Expires Sep 11, 2045

    granted
  3. US 12414995

    Bifunctional compounds comprising Apcin-A and their use in the treatment of cancer

    Northwestern University · Granted Sep 16, 2025 · Expires Sep 11, 2045

    granted
  4. US 12414999

    Compositions and methods relating to macrophages and/or monocytes with adhered particles

    The Regents of the University of California · Granted Sep 16, 2025 · Expires Sep 11, 2045

    granted
  5. US 12415779

    Processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile and polymorphs thereof

    NIKANG THERAPEUTICS, INC. · Granted Sep 16, 2025 · Expires Sep 11, 2045

    granted
  6. US 12415854

    Antibodies to TIGIT

    Arcus Biosciences, Inc. · Granted Sep 16, 2025 · Expires Sep 11, 2045

    granted
  7. US 12415856

    EGFR x CD28 multispecific antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 16, 2025 · Expires Sep 11, 2045

    granted
  8. US 12415861

    Anti C-MET antibodies

    CENTESSA PHARMACEUTICALS (UK) LIMITED · Granted Sep 16, 2025 · Expires Sep 11, 2045

    granted
  9. US 12415863

    Compositions and methods for treating cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Sep 16, 2025 · Expires Sep 11, 2045

    granted
  10. US 12415845

    Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 16, 2025 · Expires Sep 11, 2045

    granted
  11. US 12415843

    Antibody-interferon fusion proteins for enhancing adoptive T cell therapies for the treatment of cancer

    The Regents of the University of California · Granted Sep 16, 2025 · Expires Sep 11, 2045

    granted
  12. WO 2025186043

    FORMULATION PHARMACEUTIQUE POUR ANTICORPS ANTI-CCR8

    BAYER AG [DE] · Granted Sep 12, 2025 · Expires Sep 7, 2045

    granted
  13. US 2025281584

    ACTIVE VACCINATION FOR THE TREATMENT OF NGF-RELATED DISORDERS

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Sep 11, 2025 · Expires Sep 6, 2045

    granted
  14. US 12409167

    Pharmaceutical combination comprising a selective S1P1 receptor agonist

    VANDA PHARMACEUTICALS INC. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  15. US 12410209

    Modified glucocorticoids

    The Board of Regents of the University of Texas System · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  16. US 12409181

    Treatment for aortic aneurysms

    The Regents of the University of California · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  17. US 12410399

    Compositions and methods for treating retinal diseases

    The Regents of the University of California · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  18. US 12409188

    Modulators of HSD17B13 expression

    Ionis Pharmaceuticals, Inc. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  19. US 12410184

    Crystalline forms of a menin inhibitor

    Kura Oncology, Inc. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  20. US 12410153

    Compounds, compositions and methods

    AVALO THERAPEUTICS, INC. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  21. US 12409227

    Cochleates made with soy phosphatidylserine

    MATINAS BIOPHARMA NANOTECHNOLOGIES, INC. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  22. US 12410231

    Natural killer cell products and methods

    The Board of Regents of the University of Texas System · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  23. US 12410232

    Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor

    The Board of Regents of the University of Texas System · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  24. US 12410430

    Modulating apolipoprotein (A) expression

    Ionis Pharmaceuticals, Inc. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.